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Background: Several proteins involved in epigenetic regulation cause syndromic neurodevelopmental disorders
when human genes are mutated. More general involvement of epigenetic mechanisms in neurodevelopmental
phenotypes is unclear.
Methods: In an attempt to determine whether DNA methylation differentiates clinical subgroups, profiling was
performed on bisulfite converted DNA from lymphoblastoid cell lines (LCLs) in discovery (n = 20) and replication
(n = 40) cohorts of females with Rett syndrome (RTT; n = 18), autism (AUT; n = 17), seizure disorder (SEZ; n = 6),
and controls (CTL; n = 19) using Illumina HumanMethylation27 arrays. TAC1 CpGs were validated using a Sequenom
EpiTYPER assay and expression was measured in LCLs and postmortem brain. Chromatin immunoprecipitation was
performed in HEK cells. Cells were treated with valproic acid and MeCP2 binding was assessed.
Results: Two female-only cohorts were analyzed. DNA methylation profiling in a discovery cohort identified 40
CpGs that exhibited statistically significant differential methylation (≥15%) between clinical groups (P <0.01).
Hierarchical clustering and principal components analysis suggested neurodevelopmental groups were distinct
from CTL, but not from each other. In a larger and more heterogeneous replication cohort, these 40 CpG sites
suggested no clear difference between clinical groups. Pooled analysis of DNA methylation across all 60 samples
suggested only four differentially methylated CpG sites (P <0.0005), including TAC1. TAC1 promoter CpG
hypermethylation was validated in AUT and SEZ (P <0.005). Analyzed for the first time in postmortem brain, TAC1
expression was reduced in cingulate cortex in RTT and AUT+SEZ (P = 0.003). However, no significant difference in
TAC1 promoter CpG methylation was detected in RTT and AUT+SEZ brains. Additional molecular analyses revealed
that MeCP2 binds directly to the TAC1 promoter and is sensitive to antiepileptic drug treatment.
Conclusion: These data suggest that DNA methylation is not widely altered in RTT, consistent with subtle changes in
gene expression previously observed. However, TAC1 may be an important target for further functional analyses in RTT.
Studies of larger sample cohorts using primary cells that also consider shared clinical features and drug treatments may
be required to address apparent subtle disruptions of DNA methylation in neurodevelopmental disorders.
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DNA methylation is an epigenetic modification essential
for a range of cellular functions including local and
global transcription, genomic integrity, X chromosome
inactivation, and genomic imprinting [1]. Epigenetic
mechanisms are critical for a variety of neurobiological
and cognitive processes including neurogenesis, stem
cell maintenance [2], synaptic plasticity [3], learning and
memory [4], and social imprinting [5]. The importance
of epigenetic processes in normal brain function and
development is further illustrated by the presence of
neurodevelopmental deficits in syndromic disorders
caused by mutations in genes associated with these
processes. Rett syndrome (RTT), caused by mutations
in the gene encoding methyl CpG binding protein 2
(MECP2), which binds to methylated DNA, is one such
example [6].
DNA methylation is a covalent modification of the
cytosine nucleotide that occurs in vertebrates at CpG
dinucleotides to silence gene transcription directly, by
inhibiting transcription factor binding, and indirectly, by
recruiting methyl-CpG-binding proteins that engage in
chromatin remodeling activities [7]. CpG islands located
proximal to gene promoters contain a high density of CpG
sites, yet they are often hypomethylated [8]. Nonetheless,
differential DNA methylation at CpG islands, first identified
in cancer, has more recently been associated with various
neurological and neuropsychiatric disorders [1,9,10].
We investigated whether lymphoblastoid cell line (LCL)
DNA methylation profiles could be used to differentiate
related neurodevelopmental disorders into clinical categor-
ies and identify specific target genes that might be relevant
to pathophysiology. We also examined whether differential
DNA methylation identified at gene promoters in a
transformed peripheral tissue among distinct clinical
groups reflects changes in gene expression in postmortem
brain tissue. Finally, because seizures often co-occur in
the neurodevelopmental disorders examined here, we also
investigated the effects of valproic acid (VPA), a potent




Genomic DNA from females with RTT or seizure disorder
(SEZ) was obtained from the Coriell Cell Repository [11].
Genomic DNA from age-matched females with autism
(AUT) or controls (CTLs) was selected from the NIMH
Center for Collaborative Genetic Studies on Mental
Disorders Autism Pedigrees v5.0 [12]. All 60 DNA
samples (Additional file 1: Table S1) used for methylation
assays originated from LCLs. Fresh-frozen postmortem
brain samples were obtained through the Autism Speaks-
supported Autism Tissue Program at the Harvard BrainTissue Resource Center [13] or the Eunice Kennedy
Shriver National Institute of Child Health and Human
Development Brain and Tissue Bank at the University
of Maryland School of Medicine [14]. Tissue samples
of the striatum, cingulate and temporal cortices were
obtained from five RTT females and five CTL females
(Additional file 1: Table S3). Additional samples of cingulate
and temporal cortices were obtained from five AUT females
and three additional CTL females.
Genome-wide promoter CpG DNA methylation profiling
Genomic DNA was bisulfite modified using the EZ DNA
Methylation Kit (Zymo Research, Orange, CA, USA) and
hybridized to the Illumina (San Diego, CA, USA) Infinium
HumanMethylation27 BeadChip by the USC Epigenome
Center as described elsewhere [15,16]. To evaluate array
fidelity, DNA aliquots for six samples per clinical group
from the discovery cohort were included in the replication
cohort. The β values (0 to 1.0, where 0 represents no
methylation and 1 represents complete methylation)
for each CpG site were calculated as the methylated
signal intensity divided by the sum of the methylated and
unmethylated signals. Loci that possibly contained SNPs
and/or repetitive elements were removed, leaving 21,583
probes representing CpG sites in 12,936 genes for analysis.
Two AUT samples were excluded due to sex discrepancy
(Additional file 1: Figure S1). No additional major chromo-
somal abnormalities were apparent. Copy number variants
were previously reported for 11 samples included in this
study (Additional file 1: Table S4).
TAC1 DNA methylation validation
The validation experiment included 56 samples from the
Illumina discovery and replication cohorts. Another LCL
DNA aliquot was bisulfite modified using the EZ DNA
Methylation Kit (Zymo Research) by the USC Epigenome
Center, according to the manufacturer’s protocol. Genomic
DNA was isolated from gray matter dissected from the cin-
gulate cortex using the Wizard Genomic DNA Purification
Kit (Promega, Madison, WI, USA) and was bisulfite modi-
fied. Sequenom primers (Additional file 1: Table S5) were
designed to target the region that overlapped with Illumina
probe location using the EpiDesigner BETA software [17].
The Sequenom (San Diego, CA, USA) MALDI-TOF
mass spectrometry EpiTYPER Assay was performed by
the Vanderbilt University Center for Human Genetics
Research DNA Resources Core according to the manu-
facturer’s protocol.
TAC1 mRNA expression
Total RNA was isolated from LCLs using the Illustra
TriplePrep Kit (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ, USA) according to the manufacturer’s proto-
col. Total RNA was isolated from gray matter-dissected
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Kit (Qiagen, Valencia, CA, USA) according to the manufac-
turer’s protocol. RNA quality was determined using an
Agilent (Palo Alto, CA, USA) Bioanalyzer 2100 system; the
RNA integrity number was >8 for all samples. cDNA was
synthesized using the SuperScript III First Strand cDNA
Synthesis Kit (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s protocol using oligo dT primers.
Quantitative RT-PCR was performed in triplicate for each
sample using the Power SYBR Green PCR master mix
(Life Technologies Corp., Carlsbad, CA, USA) and target-
specific primers (Additional file 1: Table S4) according
to the manufacturer’s recommendations. Assays were
analyzed using a CFX96 Real-Time PCR detection system
(Bio-Rad, Hercules, CA, USA). The delta cycle threshold
(ΔCt) of target relative to ACTB was averaged per sample.
MeCP2 chromatin immunoprecipitation
The EZ-Magna ChIP A/G Chromatin Immunoprecipitation
Kit (EMD Millipore Corporation, Billerica, MA, USA)
was used with slight modifications to the manufacturer’s
protocol, as described in Additional file 1.
Valproic acid treatment
HEK cells and CTL LCLs were grown using standard
conditions. After 24 hours, media was replaced with
media containing 3 mM VPA (Sigma-Aldrich Corp., St.
Louis, MO, USA) and cells were grown for an additional
24 hours. Cells were processed for chromatin immuno-
precipitation, as described above, or genomic DNA was
extracted using a standard phenol:chloroform protocol
and bisulfite modified for the TAC1 Sequenom EpiTYPER
Assay, as described above.
Statistical analysis
lllumina probes with mean |Δβ| ≥0.15 between pairs of
clinical groups within the discovery cohort were first
selected for analysis (n = 391). Analysis of variance
(ANOVA) and the false discovery rate (FDR) were
performed to test the association between clinical group
and DNA methylation for the selected probes. Illumina
probes with P <0.01 and FDR <0.10 in the discovery
cohort were evaluated in the replication cohort and in a
pooled analysis that included all samples. Hierarchical
clustering analysis (Ward’s method) using dissimilarity
matrices (1 – Pearson’s correlation) and principal com-
ponent analysis were performed to identify subjects with
similar DNA methylation patterns. Statistical analyses
were performed using R software [18].
Tukey post-hoc analysis was performed to identify
pair-wise associations between clinical groups and DNA
methylation for the probe that was significantly differentially
methylated among clinical groups (cg14224417; TAC1).
ANOVA and Tukey post-hoc tests were performed foreach TAC1 promoter CpG site measured by the Sequenom
assay. t tests were used to assess the significance of TAC1
expression (ΔCt) stratified by clinical group for each brain
region and to assess the treatment effect in cell lines. To
investigate the association between DNA methylation and
mRNA expression in the cingulate cortex, stratified by
clinical group, we fitted linear regression models. Statistical
analyses were performed using SPSS version 18.0.3 software
(IBM, Somers, NY, USA).
Results
Genome-wide CpG DNA methylation analysis:
discovery cohort
Genome-wide DNA methylation profiling using LCLs
from females diagnosed with a neurodevelopmental
disorder and age-matched controls was performed in two
independent subject cohorts: a discovery cohort (n = 20)
and a replication cohort (n = 40). The discovery cohort
contained LCL samples from females diagnosed with RTT
(n = 10), AUT (n = 4), or CTL (n = 6) (Additional file 1:
Table S1). In discovery cohort samples, most probes had
low DNA methylation levels (median = 0.04 to 0.06;
mean = 0.21 to 0.24; range = 0.01 to 0.99). Correlations
among discovery cohort samples were similar across
probes (Pearson’s r >0.98), consistent with previous
reports [19-24].
To identify robust DNA methylation differences (Δβ), we
further analyzed all probes with pair-wise mean |Δβ| ≥0.15
among clinical groups within the discovery cohort.
This threshold generated a normally distributed dataset
containing 391 probes (Additional file 1: Table S2). Among
these probes, 127 were differentially methylated between
RTT and CTL, 104 between RTT and AUT, and 261
between AUT and CTL (Figure 1A). No probes were
differentially methylated among all three pair-wise
comparisons, but 53 probes were differentially methylated
in either RTT or AUT compared with CTL. Interestingly,
42 probes that were differentially methylated between
RTT and AUT and between AUT and CTL were opposite
in magnitude. Twenty-six probes hypermethylated in RTT
compared with AUT were hypomethylated in AUT
compared with CTL, and 16 probes hypomethylated
in RTT versus AUT were hypermethylated in AUT
versus CTL. The distribution of hypermethylation and
hypomethylation loci among comparison pairs was highly
significant (χ2(2-df ) = 14.17, P = 0.0008). RTT was
hypermethylated compared with CTL and AUT at 102
(80%) and 74 (72%) loci, respectively. AUT was also
hypermethylated compared with CTL (62%). The distri-
bution of nonoverlapping loci hypermethylated (72%)
or hypomethylated (54%) in AUT compared with CTL
was significantly different than loci hypermethylated
(82%) or hypomethylated (18%) between RTT and CTL
(χ2(1-df ) = 13.96, P = 0.0002).
Figure 1 Probes differentially methylated (Δβ ≥0.15) in neurodevelopmental disorders. (A) Venn diagrams showing 391 probes identified
as differentially methylated among Rett syndrome (RTT), autism (AUT), and control (CTL) individuals in the discovery cohort. Probes
hypermethylated in RTT and AUT or hypomethylated in RTT and AUT are also shown. (B), (C) The selected 40 probes comparing lymphoblastoid
cell line samples from females diagnosed with neurodevelopmental disorders (RTT, AUT) with CTL females were used for hierarchical clustering
and principal component analysis (PCA). (B) Hierarchical clustering of the 20 females in the discovery cohort. Each row represents an individual
and each column represents one probe. A heat map showing relative methylation differences (yellow = more methylated; red = less methylated)
is presented in the clustering dendrogram. The major dendrogram branches defined by the methylation data correspond to diagnosis (Dx), rather
than to age. (C) PCA of the 40 probe methylation profile for the 20 discovery females. Three principle components (PC1 to PC3), representing
40.7%, 22.1%, and 7.1% of the variance, respectively, are shown.
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probes identified in the discovery cohort (Additional file 1:
Table S2). Hierarchical clustering using the top 40 sig-
nificant probes (P <0.01, FDR <0.10) suggested discov-
ery samples could be classified based on their DNA
methylation profiles (Figure 1B). Principal component
analysis further suggested three distinct clusters using
the same 40 probes (Figure 1C). DNA methylation
among the 40 probes suggested more homogeneity in
RTT (mean Pearson’s r = 0.93) than among the samples in
comparison groups (mean Pearson’s r = 0.74 and 0.83 for
AUT and CTL groups, respectively).Genome-wide CpG DNA methylation: replication cohort
Because seven of the 10 RTT females in this study were
reported to have abnormal brain activity (seizures (n = 5)
or subclinical abnormal EEG activity (n = 2)], a common
feature of RTT [25], we included an additional subject
cohort in the replication experiment. We reasoned that
this would address the possibility that AEDs, which can
alter DNA methylation [26,27], might underlie some of the
differential DNA methylation observed in the discovery
cohort. The replication cohort contained LCL samples from
females with RTT (n = 8), AUT (n = 13), SEZ (n = 6), or
CTL (n = 13) (Additional file 1: Table S1). As measured
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methylation levels in these samples (median = 0.06 to 0.12;
median = 0.21 to 0.26; range = 0.01 to 0.99). Correlations
among samples were high (Pearson’s r >0.90), but less
similar than samples within the discovery cohort. To
ensure technical fidelity across assay runs, replicates
from the discovery cohort were included in the DNA
methylation analysis of the replication cohort, with
nearly perfect correlation between replicate pairs
(Pearson’s r >0.99) (Additional file 1: Figure S2). The
40 probes that distinguished clinical groups in the dis-
covery cohort analysis similarly distinguished technical
replicates, with high correlation between replicate pairs
(Pearson’s r >0.98) (Additional file 1: Figure S3). Duplicate
samples were excluded from the replication cohort analysis.
In the replication cohort, hierarchical clustering using
the 40 probes identified in the discovery cohort did not
produce clustering of DNA methylation patterns by clinical
group (Additional file 1: Figure S4A). Principal component
analysis also failed to reveal distinct clinical clusters among
the replication samples (Additional file 1: Figure S4B),
suggesting greater molecular heterogeneity among the
clinical samples included in the replication cohort.
Locus-specific DNA methylation analysis
To select particular loci with differential DNA methyla-
tion among clinical groups, we performed ANOVA for
the 40 probes from the discovery cohort analysis using
DNA methylation values from the replication cohort
samples and in a pooled analysis (Table 1). We then
selected probes below the conservative threshold of
P <0.001 and FDR <0.05 from each analysis. In the discov-
ery cohort, five loci showed significant differential DNA
methylation (HOXA11, TCN1, PTCD2, TAC1, ETNK2).
In the replication cohort, no locus was significant. In
the pooled analysis, four loci were highly significant
(PTCD2, TAC1, FLJ44881, SPAG7; P <0.0005, FDR <0.005).
Overall, no locus emerged across these three analyses.
However, TAC1 differential methylation approached signifi-
cance in the replication analysis (P = 0.003, FDR = 0.13),
and was highly significant in both discovery and pooled
analyses (P <0.0005, FDR <0.05). TAC1 was previously
implicated in RTT pathophysiology through convergent
findings in RTT patients and mouse models [28-32].
We thus selected TAC1 to target for validation.
A Sequenom EpiTYPER assay was designed to quantify
DNA methylation within the TAC1 promoter CpG
island (Figure 2A). First, we determined whether DNA
methylation levels detected at specific CpG sites within
the Sequenom target region validated the Illumina assay
results. Sequenom DNA methylation levels at two CpG
sites located closest to the Illumina probe were highly cor-
related within samples (Additional file 1: Figure S5). Next,
we evaluated whether significant differential methylationoccurred among clinical groups using the Sequenom CpG
methylation values. The clinical group had a significant
main effect on DNA methylation at TAC1 CpG site 5
(ANOVA F(3,52) = 5.70, P = 0.002). DNA methylation
levels at this site had the strongest correlation with
Illumina probe methylation values and validated the TAC1
results obtained from the genome-wide analysis.
To determine which clinical groups exhibited TAC1
differential methylation, we performed Tukey post-hoc
pair-wise comparisons for discovery, replication, and pooled
cohorts using Illumina and Sequenom data (Figure 2B). In
the Illumina dataset, TAC1 was hypomethylated in RTT
compared with AUT (P = 0.003) in the discovery cohort,
and compared with SEZ (P = 0.008) in the pooled analysis.
AUT was significantly hypermethylated relative to CTL in
discovery (P = 0.0003) and pooled analyses (P = 0.004). SEZ
was significantly hypermethylated versus CTL in replication
(P = 0.001) and pooled analyses (P = 0.0001). Sequenom
data confirmed significant AUT hypermethylation versus
CTL in discovery (P = 0.02) and pooled analyses (P = 0.04),
and SEZ hypermethylation versus CTL in replication
(P = 0.01) and pooled analyses (P = 0.002). Overall,
SEZ hypermethylation relative to CTL emerged with
the most significant differential DNA methylation in
both Illumina and Sequenom datasets.
TAC1 expression in brain
Since DNA methylation at CpG islands proximal to gene
promoter regions is an important mediator of gene
transcription [33], we evaluated whether TAC1 promoter
DNA methylation differences were associated with
differential expression. Because TAC1 is only weakly
expressed in lymphocytes [34,35], evaluating expression dif-
ferences in LCLs among clinical groups was uninformative
(Additional file 1: Figure S6). However, if altered DNA
methylation observed in LCLs occurred early in develop-
ment, then differential DNA methylation detected in LCLs
might exist in additional tissues. TAC1 is expressed in brain
throughout development [36,37], and the brain is the
primary tissue affected in neurodevelopmental disorders.
We thus examined whether TAC1 DNA methylation status
from a peripherally derived tissue correlates with central
gene expression. DNA methylation analysis revealed
significant TAC1 hypermethylation in SEZ versus CTL.
Given that seizures commonly occur in RTT [25], we
obtained postmortem brain samples from RTT females.
TAC1 expression was assayed in three brain regions from
age-matched RTT and CTL females (Additional file 1:
Table S3) using quantitative RT-PCR (Figure 3A). TAC1
expression was significantly reduced in RTT cingulate
cortex (t(6) = 2.98, P = 0.03), with a trend for reduced
expression in temporal cortex (t(8) = 2.22, P = 0.06). No
differences in TAC1 expression were detected in striatum
(t(7) = 0.54, P = 0.61). Given these results, we examined
Table 1 Top 40 differentially methylated CpG sites identified in the discovery cohort
RTT AUT CTL Discovery (n = 20) RTT AUT SEZ CTL Replication (n = 40) Pooled (n = 60)
ILMN probe Gene Mean β SD Mean β SD Mean β SD P value FDR Mean β SD Mean β SD Mean β SD Mean β SD P value FDR P value FDR
cg17950095 HOXA11 0.25 0.06 0.20 0.02 0.37 0.07 0.0002 0.03 0.23 0.12 0.27 0.11 0.27 0.09 0.25 0.12 0.86 0.92 0.42 0.46
cg00187686 TCN1 0.38 0.07 0.41 0.13 0.18 0.07 0.0002 0.03 0.48 0.14 0.40 0.09 0.43 0.05 0.37 0.06 0.05 0.32 0.003 0.02
cg04527989 PTCD2 0.83 0.04 0.64 0.11 0.83 0.06 0.0003 0.03 0.73 0.09 0.70 0.07 0.64 0.16 0.77 0.05 0.03 0.32 0.0001 0.001
cg14221171 TAC1 0.17 0.09 0.35 0.08 0.10 0.06 0.0004 0.03 0.23 0.11 0.22 0.08 0.35 0.11 0.16 0.08 0.003 0.13 0.0001 0.001
cg03718539 ETNK2 0.07 0.03 0.24 0.05 0.14 0.10 0.0004 0.03 0.11 0.03 0.12 0.06 0.16 0.06 0.09 0.04 0.07 0.32 0.02 0.05
cg09242541 APITD1 0.53 0.14 0.45 0.11 0.24 0.07 0.001 0.04 0.41 0.22 0.43 0.16 0.32 0.08 0.54 0.13 0.04 0.32 0.28 0.34
cg18432105 MYH2 0.74 0.06 0.62 0.03 0.57 0.11 0.001 0.06 0.66 0.09 0.70 0.07 0.71 0.03 0.67 0.13 0.62 0.81 0.17 0.24
cg14986136 WBP5 0.13 0.08 0.13 0.07 0.32 0.10 0.001 0.06 0.21 0.14 0.17 0.08 0.20 0.05 0.19 0.11 0.77 0.90 0.17 0.24
cg18838701 TNNI3 0.14 0.07 0.34 0.20 0.08 0.05 0.002 0.06 0.26 0.14 0.24 0.14 0.23 0.10 0.21 0.12 0.87 0.92 0.15 0.22
cg06537230 DLX5 0.29 0.09 0.35 0.05 0.16 0.06 0.002 0.06 0.27 0.09 0.30 0.08 0.37 0.09 0.29 0.09 0.20 0.65 0.02 0.05
cg19002579 SMPX 0.64 0.09 0.69 0.04 0.42 0.17 0.002 0.06 0.64 0.12 0.61 0.08 0.66 0.08 0.60 0.09 0.54 0.78 0.02 0.05
cg06618866 TLR2 0.16 0.05 0.26 0.09 0.10 0.05 0.002 0.06 0.16 0.08 0.18 0.09 0.16 0.05 0.14 0.05 0.53 0.78 0.02 0.05
cg23196831 COL14A1 0.22 0.05 0.25 0.12 0.09 0.06 0.002 0.06 0.18 0.11 0.25 0.10 0.23 0.11 0.18 0.09 0.26 0.67 0.02 0.05
cg01541443 C7orf41 0.78 0.07 0.61 0.10 0.79 0.05 0.002 0.06 0.67 0.10 0.67 0.08 0.68 0.03 0.66 0.17 0.99 0.99 0.33 0.38
cg19642007 TNNT3 0.62 0.06 0.45 0.11 0.47 0.09 0.003 0.06 0.49 0.12 0.49 0.07 0.53 0.09 0.47 0.07 0.57 0.79 0.02 0.05
cg00176210 ANK1 0.37 0.09 0.42 0.05 0.22 0.10 0.003 0.06 0.40 0.11 0.34 0.12 0.41 0.06 0.34 0.10 0.39 0.68 0.05 0.09
cg02049180 INSRR 0.65 0.07 0.43 0.19 0.64 0.03 0.003 0.06 0.62 0.11 0.62 0.07 0.64 0.04 0.61 0.09 0.92 0.95 0.23 0.31
cg09868035 C20orf135 0.45 0.07 0.38 0.11 0.29 0.07 0.003 0.07 0.45 0.10 0.44 0.13 0.41 0.07 0.38 0.12 0.49 0.78 0.04 0.09
cg26227465 IFNG 0.69 0.07 0.74 0.09 0.49 0.17 0.003 0.07 0.58 0.15 0.60 0.13 0.60 0.14 0.55 0.19 0.79 0.90 0.08 0.13
cg20322862 TGIF1 0.51 0.07 0.37 0.07 0.56 0.08 0.003 0.07 0.46 0.11 0.51 0.08 0.53 0.05 0.45 0.13 0.30 0.68 0.79 0.81
cg09404633 LMOD1 0.35 0.08 0.39 0.11 0.16 0.14 0.004 0.07 0.30 0.12 0.28 0.11 0.37 0.08 0.25 0.10 0.13 0.48 0.01 0.03
cg04555771 CACNA2D2 0.33 0.10 0.44 0.10 0.16 0.14 0.004 0.07 0.28 0.08 0.32 0.11 0.37 0.06 0.36 0.15 0.39 0.68 0.40 0.45
cg10467098 C11orf68 0.47 0.08 0.33 0.09 0.53 0.08 0.005 0.08 0.40 0.11 0.48 0.09 0.44 0.09 0.49 0.14 0.22 0.67 0.21 0.29
cg04091078 SLCO1C1 0.73 0.04 0.58 0.14 0.71 0.04 0.005 0.09 0.68 0.07 0.67 0.08 0.71 0.04 0.67 0.05 0.50 0.78 0.05 0.09
cg05570980 C3orf52 0.19 0.05 0.31 0.13 0.14 0.05 0.006 0.09 0.16 0.03 0.17 0.06 0.18 0.06 0.22 0.10 0.24 0.67 0.71 0.75
cg02441647 COL8A1 0.08 0.03 0.13 0.04 0.25 0.15 0.006 0.09 0.17 0.09 0.14 0.06 0.17 0.07 0.15 0.12 0.86 0.92 0.25 0.32
cg18801691 DCC 0.12 0.05 0.07 0.03 0.24 0.13 0.007 0.09 0.26 0.11 0.18 0.05 0.23 0.05 0.17 0.06 0.03 0.32 0.28 0.34
cg21306775 FLJ44881 0.71 0.05 0.57 0.17 0.50 0.16 0.007 0.09 0.65 0.12 0.60 0.10 0.54 0.05 0.53 0.10 0.07 0.32 0.0002 0.002
cg14141399 HAS1 0.89 0.03 0.79 0.16 0.69 0.16 0.007 0.09 0.76 0.15 0.81 0.05 0.76 0.09 0.75 0.12 0.52 0.78 0.05 0.09
cg12815142 SPAG7 0.69 0.05 0.56 0.06 0.53 0.15 0.007 0.09 0.58 0.09 0.53 0.08 0.60 0.04 0.51 0.10 0.07 0.32 0.0003 0.003
cg14062083 KRTAP13-4 0.56 0.08 0.42 0.13 0.39 0.10 0.007 0.09 0.46 0.10 0.45 0.09 0.57 0.04 0.44 0.12 0.05 0.32 0.003 0.02



















Table 1 Top 40 differentially methylated CpG sites identified in the discovery cohort (Continued)
cg00415993 F2RL2 0.67 0.10 0.65 0.11 0.44 0.18 0.008 0.09 0.58 0.08 0.51 0.13 0.59 0.07 0.44 0.19 0.10 0.42 0.002 0.01
cg00318573 CHRNA4 0.32 0.12 0.18 0.09 0.14 0.07 0.008 0.09 0.20 0.08 0.19 0.11 0.25 0.12 0.16 0.09 0.32 0.68 0.01 0.03
cg15350036 CROT 0.82 0.04 0.75 0.07 0.66 0.13 0.008 0.09 0.78 0.04 0.72 0.09 0.73 0.08 0.67 0.20 0.35 0.68 0.01 0.04
cg04993257 PLAC2 0.44 0.07 0.35 0.08 0.26 0.15 0.009 0.09 0.39 0.07 0.41 0.10 0.44 0.07 0.47 0.10 0.27 0.67 0.82 0.82
cg03273615 RBM41 0.40 0.08 0.33 0.12 0.22 0.11 0.009 0.09 0.35 0.12 0.35 0.10 0.38 0.04 0.32 0.13 0.73 0.88 0.08 0.13
cg11505048 APOBEC4 0.83 0.06 0.72 0.14 0.88 0.03 0.009 0.09 0.71 0.09 0.69 0.07 0.69 0.07 0.73 0.08 0.60 0.80 0.01 0.04
cg01145396 CHRNG 0.58 0.07 0.57 0.08 0.43 0.12 0.009 0.09 0.49 0.07 0.49 0.08 0.57 0.06 0.52 0.14 0.36 0.68 0.32 0.37
cg13370916 STARD8 0.58 0.06 0.51 0.02 0.40 0.16 0.009 0.09 0.48 0.10 0.50 0.09 0.51 0.05 0.47 0.10 0.70 0.87 0.04 0.09
Probes with P <0.001 and FDR <0.05 are in bold. Probes with P <0.01 and FDR <0.05 are in italic. AUT autism, CTL control, FDR false discovery rate, ILMN Probe Illumina HumanMethyl27 probe name; P value analysis of



















Figure 2 Physical map of the TAC1 promoter region and differential DNA methylation in lymphoblastoid cell lines. (A) TAC1 is shown
5′→ 3′ on the positive strand (chr7:97,199,050 to 97,200,050). Direction of gene transcription (arrowheads) and transcription start site (TSS; arrow)
are indicated. The differentially methylated region overlaps with a large CpG island that includes the TSS. CpG Island Track from UCSC Human
Genome Browser hg18 (black bar); Illumina (ILMN) probe (grey bar); Sequenom (SEQ) target region (white bar) with CpGs (horizontal lines);
chromatin immunoprecipitation (ChIP) PCR amplicon (striped bar). Locus diagram is drawn to scale. (B) Tukey post-hoc pair-wise comparisons of
TAC1 DNA methylation (%) assayed using ILMN (cg14221171) and validated using SEQ (CpG site 5). DNA methylation for each sample (circles) and
group mean (horizontal bar) are shown for each clinical group. *P <0.05, **P <0.01, ***P <0.005. AUT, autism; CTL, control; RTT, Rett syndrome;
SEZ, seizure disorder.
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obtained from female subjects diagnosed with AUT and
for which the patient’s cause of death was ascribed to SEZ
[38] (Figure 3B). Indeed,TAC1 expression was also reduced
in AUT+SEZ cingulate cortex, approaching signifi-
cance (t(5) = 2.29, P = 0.07). No significant difference
in TAC1 expression was detected in AUT temporal cortex
(t(7) = 0.98, P = 0.36). A combined analysis using all brain
samples and comparing TAC1 expression in the cingulate
cortex suggested a significant TAC1 reduction in affected
brains (t(12) = 3.67, P = 0.003) (Figure 3C).
TAC1 DNA methylation in brain
Several studies have reported differential DNA methylation
among brain regions in postmortem tissue [39,40].
To determine whether DNA methylation at the TAC1
promoter varied among brain regions, we selected Illumina
DNA methylation data (cg14224417) assayed in four brain
regions from female samples in a previous study [39].
The TAC1 promoter displayed significant differential
DNA methylation among certain brain regions in females
(Additional file 1: Figure S7).To determine whether the reduced TAC1 expression
observed in cingulate cortex of seizure phenotype
(RTT and AUT+SEZ) brains may be associated with
differential DNA methylation, we extracted DNA from
the same brain samples used for the expression studies
and evaluated TAC1 DNA methylation using the Sequenom
EpiTYPER assay. As expected, an inverse correlation
between TAC1 promoter DNA methylation and ex-
pression was observed for both seizure phenotype
and CTL cingulate cortex samples (Figure 3D). How-
ever, no significant differential DNA methylation was
detected at TAC1 CpG site 5 between seizure pheno-
type and CTL cingulate cortex samples (t(16) = −0.71,
P = 0.49), nor for any of the other CpG sites in the
TAC1 promoter locus (data not shown). DNA methyla-
tion at TAC1 CpG site 5 was also not a significant
predictor of TAC1 expression in the cingulate cortex of
CTL brains (β = −6.09, P = 0.78). However, in this
small sample, there was a trend suggesting DNA
methylation at TAC1 CpG site 5 may predict TAC1
expression in the cingulate cortex of seizure phenotype
brains (β = −6.40, P = 0.09).
Figure 3 (See legend on next page.)
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Figure 3 TAC1 expression and DNA methylation in the brain. (A), (B), (C) TAC1 mRNA assayed by quantitative RT-PCR in the striatum (STR),
cingulate (CCTX) and temporal cortex (TCTX) of female brains. Data are presented as relative expression of TAC1 compared with ACTB for each
sample (circles) and group mean (horizontal bar). *P <0.05; **P <0.01. (D) Scatter plot of DNA methylation at Sequenom (SEQ) CpG site 5 and
TAC1 expression in the CCTX stratified by seizure phenotype (RTT/AUT+SEZ) or control (CTL). Regression lines for seizure phenotype (black) and
CTL (dashed) indicate an inverse relationship between DNA methylation and expression in CCTX. AUT, autism; RTT, Rett syndrome; SEZ,
seizure disorder.
Figure 4 MeCP2 binding to the TAC1 promoter in vivo.
(A) Chromatin immunoprecipitation(ChIP) assay in untreated and 3
mM valproic acid (VPA)-treated HEK cells. DNA fragments
immunoprecipitated with IgG, anti-MeCP2 or anti-acetyl histone H3
(Ac-H3) were analyzed by PCR with primers specific for the TAC1
promoter locus (Figure 2A). (B) Reduced MeCP2 and increased
Ac-H3 occupancy at the TAC1 promoter in DNA extracted from
untreated (black) or VPA-treated (grey) HEK cells, assayed in triplicate
by quantitative PCR analysis of ChIP samples. Ac-H3 quantification
extends beyond the graph to 105% input.
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RTT is mostly caused by MECP2 coding mutations [6].
More recently, increased MECP2 expression was detected
in temporal cortex of patients with intractable temporal
lobe epilepsy [41]. To determine whether TAC1 is a
MeCP2 target in vivo, we performed chromatin immu-
noprecipitation assays in HEK cells, which express
high levels of TAC1 [34,35]. Anti-MeCP2 specifically
precipitates TAC1 DNA, while control IgG yields no
enrichment of binding to the TAC1 sequence (Figure 4A),
supporting direct binding of MeCP2 to the TAC1 promoter
region (Figure 2A). We further examined the possibility
that DNA hypermethylation detected at the TAC1
promoter in seizure-associated phenotypes was due to
AED treatment. VPA is an anticonvulsant, commonly
administered for seizure control in RTT, and a potent
histone deacetylase inhibitor that can directly alter
DNA methylation in vitro [26]. Following VPA treatment
of HEK cells, anti-MeCP2 failed to precipitate TAC1
DNA, whereas anti-acetylated histone 3 precipitates more
DNA, as expected (Figure 4A, B).
Discussion
The present study demonstrates both the challenges
and potential promise of utilizing genome-wide DNA
methylation patterns in LCLs derived from peripheral cells
to distinguish individuals with different neurodevelopmental
disorders. An initial analysis of LCLs from CTLs and
the neurodevelopmental disorders RTT and AUT was
sufficiently specific to cluster each cohort. However, a
larger replication sample did not repeat this finding.
Importantly, the additional subject analyses revealed
that secondary clinical complications that can accompany
many neurodevelopmental disorders, such as SEZ,
may have significant effects on DNA methylation status. In
contrast to diseases like cancer [42], alterations in genome-
wide DNA methylation patterns in neurodevelopmental
disorders are likely to be subtle. We therefore suggest that
utilizing samples from patients with detailed clinical and
molecular information on each subject included in such
studies will be required to discover unique disorder-specific
DNA methylation patterns that will be useful for sorting
clinical heterogeneity within and across disorders.
Analysis across all clinical groups suggested differential
methylation of the TAC1 gene in LCLs derived fromperipheral cells. This turned out to be highly relevant
with regard to RTT, given that it is one of the few genes
whose expression is consistently reduced in the brains of
Mecp2 mutant mice [31,32]. Our study is the first to
examine TAC1 expression in postmortem brain samples
from RTT subjects. We demonstrate reduced TAC1
expression in brain samples from subjects defined by
clinical diagnosis and presence of seizures. The principle
protein responsible for DNA methylation-dependent
transcriptional regulation is MeCP2, encoded by a gene
mutated in RTT. Further analysis showed direct
MeCP2–TAC1 promoter binding, but also suggested that
the interaction is highly sensitive to the AED VPA in vitro.
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ing epigenetic differences in categorical analyses based on
a clinical diagnosis. The challenges and utility of the
approaches used here are discussed below.
Challenges of clinical stratification using differential DNA
methylation patterns
DNA methylation is one of several key mechanisms
through which gene expression is controlled. Analysis of
DNA methylation patterns has been the focus of com-
parative studies in normal and malignant tissues [43],
biopsied samples from peripheral organs [44-46], and in
white blood cells from control and disorder-diagnosed
populations [21,47,48]. This strategy is a challenge par-
ticularly with neurological disorders, because molecular
assays of brain are often not possible in patients. Several
studies have examined DNA methylation patterns in
postmortem brain tissue from control subjects and those
with a psychiatric disorder diagnosis [49,50], but the
relationship between peripheral and central measures of
DNA methylation are only beginning to emerge [45].
Moreover, there is variability in the fidelity of different
assays used in studies, and few studies use secondary
methods to validate alternations in specific DNA methyla-
tion sites. The 27K chip has been shown to be highly reli-
able and sensitive across assay runs [19,23], and we showed
in the present study that replicate samples run at different
times, independent of diagnostic group, are >99% identical
in terms of global DNA methylation patterns. One caveat
of our study was the use of the 27K chip, the only validated
chip at the time we initiated the studies. This chip has high
fidelity and samples CpG sites across the genome, although
it only probes approximately one-half of the genes in the
genome. Future studies using assays with greater coverage
will therefore possibly reveal new patterns of DNA methy-
lation not recognized here. An additional technical caveat is
the use of patient LCLs. These cells provide an opportunity
to assess patient-derived samples that are commonly ac-
cumulated in repositories in sufficient numbers for the
study of rare neurological disorders. However, the trans-
formation and growth processes of these cell lines may
lead to epigenetic changes not present in the primary
patient cells [51]. These challenges notwithstanding, the
present study emphasizes the importance of controlling
for complex clinical phenotypes, such as seizures. The
data presented here suggest that the state-dependent
status of DNA methylation patterns, as well as central
and peripheral differences, may make it challenging to
detect disorder-specific patterns that consistently reflect
categorical differences across samples.
DNA methylation in Rett syndrome
We initially focused on RTT due to the importance of
MeCP2 in regulating transcription through binding tomethylated DNA. The possibility of altered DNA methy-
lation in RTT had not previously been investigated in
clinical samples. We hypothesized that the altered
MeCP2 function in RTT might lead to compensatory
changes in the DNA methylation status of certain genes.
In fact, the initial sample illustrated that using LCLs
from patients, analyzed using cluster and principle com-
ponent methods of the top differentially methylated
genes, distinguished the clinical groups from CTL. More
than double the number of CpG sites showed differential
DNA methylation between AUT and CTL (n = 261) than
between RTT and CTL (n = 127). At first glance, these
results were surprising given our hypothesis that RTT
would display the greatest differential DNA methylation
from CTL because of the involvement of MeCP2 in this
disorder. However, the more limited differences in the
first RTT cohort are not unprecedented. For example, in
another neurodevelopmental disorder, Cornelia de Lange
syndrome, fewer CpG sites demonstrated differential
methylation than the number of genes with expression
differences [52,53]. Expression profiling in AUT has
been more compelling than in RTT. Hundreds of differ-
entially expressed genes in LCLs and brain from AUT
subjects have been reported [54,55], while global gene
expression analyses have failed to reveal any dramatic
differences in RTT compared with control subjects using
a variety of tissues [56-61]. The present data showing an
inverse correlation between DNA methylation and TAC1
expression, despite the reduced TAC1 expression in cor-
tex, may be a reflection of the small sample size and/or
the complex relationship between transcriptional regula-
tion and gene expression.
The initial promise of categorizing clinical groups by
DNA methylation pattern from the first cohort did not
replicate in a second, larger sample that included LCLs
from individuals with SEZ. DNA methylation status is
highly influenced by nonheritable factors, including
physiological state [62], medications [26] and even diet
[63]. We reasoned that since the presence of seizures in
neurodevelopmental disorders is common and a hall-
mark of RTT, it could serve as a unifying feature in the
clinically diagnosed populations. In fact, using LCLs
from subjects with SEZ and postmortem brain tissue
from AUT cases in which seizures were noted in the
medical history, or was the cause of death, we show that
DNA methylation patterns of specific genes may be
more related to seizure status, a finding that has not
been previously reported. The repositories that provided
the LCLs and postmortem brain samples do not collect
sufficient information regarding medication status. We
can therefore only suggest that contributions to DNA
methylation status at certain sites may be due in part to
drug treatment effects. To investigate this possibility,
VPA-treated HEK cells showed dramatic changes in
Aldinger et al. Journal of Neurodevelopmental Disorders 2013, 5:15 Page 12 of 14
http://www.jneurodevdisorders.com/content/5/1/15DNA methylation of the TAC1 gene; additional sites
were probably also impacted by VPA. Interestingly, VPA
treatment altered MeCP2 binding to the TAC1 promoter,
which suggests that this putative regulatory interaction
may be responsible in part for the consistent reduction
of TAC1 expression in cortical brain regions that we
assayed, although not in striatum.
TAC1 as a target gene in Rett syndrome
The TAC1 DNA methylation and gene expression changes
were not expected, although this gene has been a candidate
target in RTT due to the finding of reduced expression in
Mecp2 mutant mice [31,32]. The present study is the first
to identify molecular changes of TAC1 in brain samples
from RTT patients. TAC1 gene expression changes were
statistically significant in the cingulate cortex, with a trend
that almost reached significance in the temporal cortex
given the limited sample size; other brain regions should
be evaluated in the future. It is noteworthy that TAC1
expression changes were not observed in the striatum,
indicating that seizure pathophysiology and AEDs do
not produce global, nonspecific effects throughout the
brain. The alterations in the cingulate cortex are of
functional interest, due to the role of this cortical region
in executive function and complex multisensory pro-
cessing [64-66], both of which are disrupted in AUT and
SEZ [67,68]. The TAC1 gene encodes neurokinins and
substance P. These neuromodulators are expressed in
nociceptive primary sensory neurons, and serve as mod-
ulators of pain perception and inflammation [69]. In the
neocortex, substance P is an excitatory neuromodulator
of projection neuron activity [70]. Furthermore, there
are several convergent findings related to expression of
this peptide and RTT. First, substance P is reduced in
the cerebrospinal fluid of RTT patients [28]. Second,
substance P immunoreactivity is reduced in brains of
RTT patients compared with age-matched controls [30],
although not in the bowels (enteric nervous system) [29].
Third, Tac1 expression is reduced in the hypothalamus of
juvenile male Mecp2 mutant mice [31] and in adult male
mice with postnatal Mecp2 loss [32]. Finally, respiratory
abnormalities are a clinical hallmark of RTT [71] and
neurons in the rhythm-generating center of the respiratory
network are dynamically regulated by substance P [72].
The discovery of TAC1 deficiency in RTT thus adds to
other convergent lines of evidence implicating the neuro-
peptides in RTT pathophysiology. Further consideration of
substance P and other neuropeptides transcribed from the
TAC1 locus as therapeutic targets in RTT and AUT+SEZ
is warranted.
Conclusion
We have examined genome-wide CpG DNA methylation
patterns in LCLs from females with three relatedneurodevelopmental disorders. The initial analysis sug-
gested promise of differential DNA methylation patterns
among clinical disorders, but failure to replicate this find-
ing in a second, larger cohort may reflect a more complex
relationship between DNA methylation status and neuro-
logical disorder. This may be due to the presence of
seizures in neurodevelopmental disorders and/or the use
of medications that can affect DNA methylation, such as
VPA. Currently, there is a limited understanding of the
complex relationship between DNA methylation status of
peripheral cells and brain tissues. Interestingly, we found
that hypermethylation at the TAC1 promoter in LCLs was
correlated with reduced expression in certain brain regions,
despite the lack of a change in DNA methylation of the
TAC1 promoter in the brain. Further, we show that MeCP2
directly binds to the TAC1 promoter in vivo, and this
binding can be altered dramatically by AED treatment.
These findings suggest that future studies with larger
sample cohorts should consider shared co-occurring
clinical features, such as seizures, as well as specific drug
treatments in order to more thoroughly address the role of
altered DNA methylation in neurodevelopmental disorders.Availability of supporting data
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